AU2021356687A1 - Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride - Google Patents

Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride Download PDF

Info

Publication number
AU2021356687A1
AU2021356687A1 AU2021356687A AU2021356687A AU2021356687A1 AU 2021356687 A1 AU2021356687 A1 AU 2021356687A1 AU 2021356687 A AU2021356687 A AU 2021356687A AU 2021356687 A AU2021356687 A AU 2021356687A AU 2021356687 A1 AU2021356687 A1 AU 2021356687A1
Authority
AU
Australia
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
subject
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021356687A
Other languages
English (en)
Other versions
AU2021356687A9 (en
Inventor
Michael De Vivo
Friso POSTMA
Robert RISINGER
Frank Yocca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxcel Therapeutics Inc
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Publication of AU2021356687A1 publication Critical patent/AU2021356687A1/en
Publication of AU2021356687A9 publication Critical patent/AU2021356687A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021356687A 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride Abandoned AU2021356687A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (2)

Publication Number Publication Date
AU2021356687A1 true AU2021356687A1 (en) 2023-06-15
AU2021356687A9 AU2021356687A9 (en) 2024-10-03

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021356687A Abandoned AU2021356687A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Country Status (11)

Country Link
US (1) US20240024289A1 (https=)
EP (1) EP4225305A4 (https=)
JP (1) JP2023545372A (https=)
KR (1) KR20230084186A (https=)
CN (1) CN116615243A (https=)
AU (1) AU2021356687A1 (https=)
CA (1) CA3195133A1 (https=)
IL (1) IL301971A (https=)
MX (1) MX2023003993A (https=)
TW (1) TW202228682A (https=)
WO (1) WO2022076818A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2884926C (en) * 2012-10-15 2021-09-21 Orion Corporation A veterinary method of alleviating noise aversion
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
IL267689B2 (en) * 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
BR112022000992A2 (pt) * 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes

Also Published As

Publication number Publication date
CN116615243A (zh) 2023-08-18
IL301971A (en) 2023-06-01
MX2023003993A (es) 2023-05-24
JP2023545372A (ja) 2023-10-30
CA3195133A1 (en) 2022-04-14
WO2022076818A1 (en) 2022-04-14
EP4225305A1 (en) 2023-08-16
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25
AU2021356687A9 (en) 2024-10-03
KR20230084186A (ko) 2023-06-12
EP4225305A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
US11998529B2 (en) Non-sedating dexmedetomidine treatment regimens
US20240024289A1 (en) Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
US20250319069A1 (en) Methods for treating depressive states
JP2006508122A (ja) チザニジンの頬及び舌下デリバリーのための医薬組成物及び投与形態並びにチザニジンを舌下又は頬に投与する方法
WO2024263973A1 (en) Dexmedetomidine treatment regimens
TW202610650A (zh) 用於增強鎮靜之咪達唑侖及氯胺酮
CN117750956A (zh) 用于治疗抑郁状态的方法
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period